A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
Clinical trial NCT00517530 · COMPLETED
Trial details
- NCT number
- NCT00517530
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-09-01
- Primary completion
- 2013-11-01
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.